Syngene stock extends Bristol Myers Squibb partnership to 2035
Published on 11/20/2026 at 02:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSyngene broadens BMS collaboration
- The expanded relationship covers discovery, translational sciences, development, manufacturing, clinical trials, data and information technology services.
- Syngene plans to build capabilities and infrastructure with a longer-term horizon for future programs.
Syngene International said on Monday, November 16, that it had extended its long-term strategic research collaboration with Bristol Myers Squibb through 2035. The Economic Times reported the announcement on Wednesday, November 18.
Broader services strengthen partnership
The expanded agreement covers integrated services across discovery, translational sciences, pharmaceutical development and manufacturing, clinical trials, data and information technology. Syngene said the arrangement is intended to support the progression of programs from research to commercialisation.
The companies began working together in 1998 and established the Biocon Bristol Myers Squibb Research and Development Center, which Syngene describes as its first dedicated research and development center. Syngene Managing Director and CEO Peter Bains said the extended relationship will support joint planning for new capabilities and infrastructure.
Integrated platform remains central
Syngene provides integrated research, development and manufacturing services from early discovery to commercial supply. Its activities cover pharmaceutical, nutrition, animal health, consumer goods and speciality chemical companies, with capabilities spanning small and large molecules.
Company profile
Syngene International is an integrated research, development and manufacturing organisation serving clients across the life sciences and related industries. Its platform combines therapeutic discovery, development services and manufacturing support across the drug development lifecycle. The company operates dedicated scientific centres and client-focused research infrastructure in India.
Syngene International at a glance
- Company: Syngene International Limited
- ISIN: INE398R01022
- Business: Integrated research, development and manufacturing services
- Strategic partner: Bristol Myers Squibb
- Announcement reported: November 18, 2026
India's broader equity backdrop can be followed through the BSE Sensex market environment.
More news and analyses on Syngene stock are available here.
